Elevated Level of Plasma Basic Fibroblast Growth Factor in Multiple Myeloma Correlates with Increased Disease Activity
暂无分享,去创建一个
M. Kizaki | Y. Ikeda | T. Kamata | J. Hata | Taketo Yamada | S. Okamoto | Wenlin Du | Y. Hattori | C. Kawamura | Naoki Shimada | N. Sato | Tsunayuki Kakimoto | Y. Ote | Du Wenlin | Chiharu Kawamura | Wenlin Du
[1] K. Wernecke,et al. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma , 2001, European journal of haematology.
[2] H. Joensuu,et al. Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. , 2000, Blood.
[3] E. Estey,et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. , 2000, Blood.
[4] R. Fonseca,et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] P. L. Bergsagel,et al. Ectopic expression of fibroblast growth factor receptor 3 promotes myeloma cell proliferation and prevents apoptosis. , 2000, Blood.
[6] G. Tricot. New insights into role of microenvironment in multiple myeloma , 2000, The Lancet.
[7] M. Taniwaki,et al. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation. , 1999, International journal of oncology.
[8] H. Joensuu,et al. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma. , 1999, Blood.
[9] D. Ribatti,et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. , 1999, Blood.
[10] T. Grogan,et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. , 1999, Cancer research.
[11] E. Ingham,et al. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. , 1998, British Journal of Cancer.
[12] E. Schröck,et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3 , 1997, Nature Genetics.
[13] S. Sallan,et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. , 1997, The American journal of pathology.
[14] A. Waage,et al. Hepatocyte growth factor and its receptor c-met in multiple myeloma. , 1996, Blood.
[15] E. Calleja,et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. , 1996, Blood.
[16] D. Ribatti,et al. Angiogenesis in B cell lymphoproliferative diseases. Biological and clinical studies. , 1995, Leukemia & lymphoma.
[17] J. Isner,et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.
[18] D. Ribatti,et al. Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA‐1, VLA‐4, LAM‐1, and CD44 , 1995, American journal of hematology.
[19] D. Ribatti,et al. Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.
[20] M. Brizzi,et al. The hepatocyte growth factor and its receptor , 1993, Stem cells.
[21] T. Sugimura,et al. K-sam-related gene, N-sam, encodes fibroblast growth factor receptor and is expressed in T-lymphocytic tumors. , 1992, Cancer research.
[22] T. Sugimura,et al. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. , 1991, Biochemical and biophysical research communications.
[23] H. Asaoku,et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.
[24] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[25] A I Pick,et al. THE TREATMENT OF MULTIPLE MYELOMA , 1948, Harefuah.
[26] F. Di Raimondo,et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. , 2000, Haematologica.
[27] M. Oken. Multiple myeloma: prognosis and standard treatment. , 1997, Cancer investigation.
[28] P. Vermeulen,et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. , 1997, British Journal of Cancer.